Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

In October 2024, Novartis announced that based on its review of 48-week data from the Phase 3 MANIFEST-2 study, longer follow-up time is needed to determine the regulatory path for pelabresib in ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Move37 is an AI company founded in 2015, predating the widespread recognition of generative AI sparked by ChatGPT. However, unlike ChatGPT, the company’s focus has remained on offering AI-based tools ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

Non-US companies can also take up 10% of the ... Nondividend payers, such as the fund's positions in Vertex Pharmaceuticals and Royal Caribbean Group, are capped at 5%. While the strategy has ...

The managers have typically avoided biotechnology, but added Regeneron Pharmaceuticals REGN in 2020 and then Vertex Pharmaceuticals ... especially in non-U.S. strategies. Hartford leaves most ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.